IONS Ionis Pharmaceuticals Inc.
69.08
+1.6 (+2%)
Previous Close
67.48
Open
67.71
Price To Book
7.65
Market Cap
9,705,760,586
Shares
140,500,298
Volume
626,393
Short Ratio
Av. Daily Volume
1,075,572
NewsSee all news
- Ionis Pharmaceuticals, Inc. (IONS) Q2 2019 Earnings Call Transcript
- Ionis Pharmaceuticals Looks to Partners to Pay the Bills
- Market Takes Off After Tariffs Pushed Back
- Edited Transcript of IONS earnings conference call or presentation 7-Aug-19 3:30pm GMT
- 3 Charts That Suggest Now Is the Time to Buy Into Biotech
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 1/2 trial initiation announced October 13, 2017.
IONIS-MAPTRx
Alzheimer's disease
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 3 trial to be initiated 2H 2019.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.
Phase 2 trial to be initiated early 2019.
IONIS-FB-LRx
Geographic Atrophy (GA)
Latest News
- Ionis Pharmaceuticals, Inc. (IONS) Q2 2019 Earnings Call Transcript
- Ionis Pharmaceuticals Looks to Partners to Pay the Bills
- Market Takes Off After Tariffs Pushed Back
- Edited Transcript of IONS earnings conference call or presentation 7-Aug-19 3:30pm GMT
- 3 Charts That Suggest Now Is the Time to Buy Into Biotech
- New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
- Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
- The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout
- Ionis Reports Second Quarter 2019 Financial Results
- Akcea Reports Financial Results and Highlights for Second Quarter 2019
- Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
- Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
- Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
- Rate Cut Wait Almost Over
- Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
- Ionis Pharmaceuticals Inc (IONS) Chairman & CEO Stanley T Crooke Sold $702,500 of Shares
- Ionis Pharmaceuticals IONS- 2019 Top Picks' Mid-Year Update
- Late Surge Helps S&P Join NASDAQ in the Green
- Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients